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Frequent allelic imbalances (AIs) including loss of heterozygosity and microsatellite instability on a specific chromosomal region have
been identified in a variety of human malignancies. The objective of our study was to assess the possibility of prognostication and
monitoring of oral squamous cell carcinoma (SCC) by microsatellite blood assay. DNA from normal and tumorous tissues and serum
DNA obtained at three time points (preoperatively, postoperatively, and 4 weeks postoperatively) from 64 patients with oral SCC
was examined at nine microsatellite loci. In all, 38 (59%) DNA samples from tumorous tissues and 52% from serum showed AIs in at
least one locus. Patterns of AIs in the serum DNA were matched to those detected in tumour DNA. Of them, AIs were frequently
detected preoperatively (44%, 28 of 64), and postoperatively (20%, 13 of 64). Moreover, among 12 cases with AIs during the
postoperative period, six had no evidence of an AI 4 weeks postoperatively, and they had no recurrence and were disease free.
In contrast, six patients with AI-positive DNA 4 weeks postoperatively have died with distant metastasis within 44 weeks. Thus, our
results suggest that the assessment of microsatellite status in the serum DNA could be a useful predictive tool to monitor disease
prognosis.
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Squamous cell carcinoma (SCC), which contributes to more than
90% of all malignant tumours of the oral cavity, is characterised by
regional and distant metastases. Most patients with oral SCC who
have either suspected or proven metastases in the regional lymph
nodes are candidates for composite resection in which the lesion,
surrounding tissues, and lymph nodes of the neck are all removed.
Since oral tumours, if undetected, frequently may metastasise to
solitary lung tumours, early and sensitive detection of the
metastasis is of primary importance and requires close surveillance
for successful treatment. Despite its clinical importance, at present
there is no predictive procedure related to the recurrence,
metastasis, or both.
It is widely accepted that the accumulation of genetic damage
is a major cause of the development of human malignancies
including oral SCC (Scully et al, 2000; Williams, 2000). Thus, DNA
can provide one of the most direct sources for potential markers.
As sample materials for diagnosis should be easily accessible by a
minimally invasive procedure, there has been much interest in the
potential use of nucleic acid markers in the blood of patients with
cancer. Allelic imbalances (AIs) appearing as loss of heterozygosity
(LOH) or as microsatellite instability (MSI) have been detected in
the circulating DNA of patients with a variety of malignancies,
such as non-small-cell lung cancer (Sozzi et al, 1999), renal cell
carcinoma (Gonzalgo et al, 2002), bladder cancer (Utting et al,
2002), breast cancer (Silva et al, 1999), colon cancer (Diep et al,
2003), and malignant melanoma (Taback et al, 2004). Nawroz et al
(1996) first demonstrated that AIs could be detected in the plasma/
serum DNA of head and neck SCC, suggesting that circulating
tumour-associated DNA in the blood of patients with oral SCC can
be a key determinant in predicting tumour recurrences or
metastasis.
In the present study, we evaluated the microsatellite status of
serum-isolated DNA preoperatively, postoperatively, and 4 weeks
postoperatively from patients with oral SCC using nine micro-
satellite markers recently reported to be frequent loci showing AIs
in primary oral SCCs.
MATERIALS AND METHODS
Patients
In all, 64 patients (38 males and 26 females; mean age, 68 years;
range, 39–81 years) who underwent primary oral SCC resection at
the Division of Dentistry and Oral-Maxillofacial Surgery, Chiba
University Hospital from 2000 to 2004 were selected to participate
in the present study. No patients underwent a blood transfusion.
Informed consent was obtained from all patients and the patients’
families, and our protocol was reviewed and approved by the
institutional review board of Chiba University.
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sHistopathologic diagnosis of each neoplastic tissue was per-
formed according to the World Health Organization criteria by the
Department of Pathology, Chiba University Hospital, and all
resected tumours had been histopathologically diagnosed with
tumour-free margins. Clinicopathologic staging was determined by
the TNM classification of the International Union against Cancer.
Among the 64 patients with oral SCC, three were in stage I, 14 in
stage II, 23 in stage III, and 25 in stage IV. Prospective follow-up,
starting after surgery, and diagnosis was based on regular (every
month during the first year and every 3 months during the second
year) clinical, biochemical, and radiologic examinations, including
bone scans.
DNA isolation
Peripheral blood (5ml) samples were collected preoperatively,
postoperatively, and 4 weeks postoperatively. Blood samples were
centrifuged in EDTA tubes for 10min at 3000g to obtain the serum
from the supernatant. Tumour tissues were obtained at the time of
surgical resection. Resected tissues were immediately snap-frozen
in liquid nitrogen. The peripheral lymphocytes of each patient
were used as a source of normal DNA.
DNA was extracted from tissue, sera, and lymphocytes using
a QIAamp Blood and Tissue Kit (Qiagen, Hilden, Germany) as
recommended by the manufacturer. The extracted DNA was eluted
in 100ml of sterile water and stored at  201C until analysis.
Microsatellite analysis
Nine microsatellite markers on seven chromosome arms were
selected for high polymorphism, small size of amplified fragment,
and location at sites frequently undergoing AIs in oral SCC. The
following microsatellite markers purchased from Research Genetics
(Huntsville, AL, USA) were selected based on previous reports
(Uzawa et al, 1994, 1996; Gonzalez et al, 1995; Watanabe et al,
1997; Miyakawa et al, 1998; Ogawara et al, 1998; Nakanishi et al,
1999): D5S178 (5q21), D9S104 (9p21), IFNA (9p22), D11S910
(11q23), D11S1356 (11q25), D13S273 (13q14–21), TP53 (17p13),
D18S46 (18q21), and D22S274 (22q13). Polymerase chain reaction
(PCR) amplification was carried out in a 25-ml final volume
containing 0.6U of Taq polymerase in PCR buffer (50mM KCl,
10mM Tris-Cl (pH 8.0), 1.5mM MgCl2), 80mM of each dNTP, and
10pmol of each primer. Samples were processed through 32 cycles,
with each cycle consisting of 1min at 941C, 1min at an annealing
temperature of 55–571C (as appropriate for each primer), and
1min at 721C. A negative control without DNA was included in
every PCR series. The amplified PCR products were loaded in
parallel on 5% polyacrylamide gel containing 7 M urea and
visualised by silver staining.
The normal pattern at each microsatellite in each individual was
defined as the pattern in each corresponding normal tissue. Loss
of heterozygosity was assessed by scanning densitometry, analysed
by National Institutes of Health (NIH) software (Image version
1.62, Dr W Rasband, NIH, Bethesda, MD, USA), and then
diagnosed as the signal intensity in cancer-associated DNA, that
is, less than 30% of that of control DNA from the identical patient.
Alterations were designated as MSI when any band that was not
seen in normal DNA appeared in tumour-associated DNA.
Duplicate examinations were performed to confirm AIs in each
subject.
Statistical analysis
Significant differences were calculated by Fisher’s exact test. One-
tailed P-values less than 0.05 were considered statistically
significant.
RESULTS
In all, 192 blood samples were collected from 64 subjects at the
three time points. In addition to sera, genomic DNA from 64 pairs
of tumour samples and normal controls were isolated. Overall, 320
DNA samples were evaluated by microsatellite analysis.
Using a panel of nine microsatellite markers, we checked for the
presence of tumour-associated DNA in the serum by comparing
the markers with each normal control in the 64 patients with oral
SCC. Sporadic AIs in DNA from tumour tissues were observed
in 59% (38 of 64) of the patients in at least one or more loci
examined. Table 1 shows microsatellite alteration status in all
patients with AIs (n¼38). Of them, five patients had only one AI
in tumour tissue DNA without AI in the serum obtained at any
time point. Therefore, it was possible to detect at least one AI in
the serum DNA in 87% (33 of 38) of the patients with AI in tumour
DNA, suggesting the presence of circulating tumour DNA. All AI
patterns in sera were matched to those detected in tumour DNA
from the identical patients, indicating that the presence of AI in the
serum was associated with the presence of AI in paired tumour.
Free-circulating tumour-associated DNA was detected preopera-
tively (44%, 28 of 64) and postoperatively (20%, 13 of 64). Among
the patients with AI preoperatively (n¼28), 20 (71%) had no
evidence of AI in sera postoperatively, they have had no recurrence
or distant metastasis, and are disease free. In contrast to AI-free
patients, two patients with AI-positive DNA 4 weeks postopera-
tively died with distant metastasis within 44 weeks after surgery.
We detected a significant correlation between the presence of
AIs in the serum DNA and tumour stage (P¼0.0378, stage I/II vs
stage III/V). However, the presence of serum DNA alterations did
not correlate with other clinical parameters, such as tobacco use,
alcohol consumption, age, tumour differentiation, or lymph node
status.
The most frequently altered chromosome in the serum DNA
was at the IFNA locus on 9p21 (40%, 15 of 38), where p16 and p15
tumour suppressor genes are in close proximity. All IFNA AIs were
observed in patients with oral SCC classified as stage III or IV
disease with the exception of one stage II case. Typical examples of
the microsatellite analysis are shown in Figure 1.
DISCUSSION
The circulating DNA in the plasma or serum of patients with
cancer has been shown to reflect the characteristics of the tumour
DNA including molecular changes, such as methylation, point
mutations, and MSI. The first description regarding the use of
microsatellite polymorphic markers to identify and characterise
circulating tumour DNA in patients with head and neck SCCs,
including oral SCCs, was that of Nawroz et al (1996). A number
of recent reports suggested that tumour-associated DNA in the
serum may be a tool for early diagnosis or prognosis in a wide
variety of cancers. In the current study, we evaluated the
hypothesis that detecting circulating tumour-associated DNA
using tumour-specific AIs might have clinical use in oral SCC,
and our data on oral SCC suggest that the detection of free-
circulating tumour-associated DNA during the postoperative
period may be of prognostic value.
The sensitivity of microsatellite analysis in the serum from head
and neck SCC including oral SCC has differed from study to study.
For example, while Coulet et al (2000) found that only 2% of
patients with head and neck cancer had AIs, higher incidences of
AIs were detected (between 18.7 and 45%) (Nunes et al, 2001;
Nawroz-Danish et al, 2004).
We carried out microsatellite analysis using nine markers on
serum samples obtained at three time points in 64 patients with
oral SCC. In all 52% (33 of 64) of patients had AIs for at least one
or more loci or period in their serum identical to tumour DNA.
Since we selected serum samples at different time points with high
Oral cancer serum DNA analysis
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spolymorphic markers, the high prevalence of AIs could be detected
in this study.
We also found that there was a strong statistical correlation
between the presence of AIs in the serum DNA and tumour stage
(Po0.05, stage I/II vs stage III/V), which has been considered one
of the most important prognostic determinants. The detection of
AIs in the serum should be considered an attractive approach for
predicting the prognosis of patients with oral SCC.
The most frequent marker with AI was the IFNA locus at 9p21,
where p16 and p15 tumour suppressor genes frequently mutated,
deleted, and methylated in various types of human cancers are in
close proximity. In addition, vast majority of AIs at the IFNA locus
were observed in advanced oral SCCs (stage III or IV), suggesting
that this chromosomal abnormality possibly associated with the
inactivation of p16 and p15 may contribute to the progression of
this disease. In this context, the presence of a chromosomal
deletion at the 9p21 locus has been reported to be linked to local,
regional, or distant recurrence in head and neck SCCs (Lydiatt
et al, 1998).
It is of interest to note that while most AI-positive patients (84%,
32 of 38) had lost the tumour-associated DNA in their serum by
4 weeks postoperatively, AI in the serum DNA still was detected
in six patients 4 weeks after surgery, and those patients had a poor
prognosis with distant metastasis. Furthermore, Figure 1 also
shows that the AI was detected not only in tumour DNA but also in
Table 1 Microsatellite status of patients with OSCCs
Figure 1 Representative results of the microsatellite analysis at the IFNA
locus of a lymphocyte (lane 1), preoperative sera (lane 2), postoperative
sera (lane 3), sera 4 weeks postoperatively (lane 4), and tumour (lane 5)
from a patient with oral SCC (case P24). While DNA from lymphocyte
reveals two major silver-stained bands, LOH of top alleles are detected in
DNA from sera at all time points and from tumour tissue.
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sthe serum at all time points. At present, we have no exact
explanation as to why these patients still had AIs even at the last
time point examined. However, the proposed mechanisms may
include: (1) differences in activation of their tumour cells; (2)
differences in the number of tumour cells; and (3) decline of their
autoimmune systems.
In conclusion, based on this pilot study of 64 patients with nine
markers, microsatellite analysis at three time points in their
treatment may predict the risk of future recurrence and death.
Thus, we propose that the microsatellite blood assay should be
considered as a clinically important monitoring tool for assessing
patient response to adjuvant therapy and in the surveillance of
patients who are clinically disease free for the earliest signs of
recurrence or distant metastasis. Larger prospective randomised
trials are needed to validate the clinical utility of our findings.
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